pipeline

Advanced Pipeline

• CardiAMP – autologous minimally processed bone marrow cells (a patient’s own cells)

• CardiAllo MSC –allogenic culture expanded mesenchymal stem cells derived from bone marrow  (donor-derived)  

  Both programs provide compelling and synergistic approaches to replicating the natural response of bone marrow cells to cardiac injury. CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, using a pre-procedure screening test to identify patients most likely to benefit from the therapy.  CardiAllo MSCs utilize younger, universal donor mesenchymal stem cells and may be appropriate for patients who are not optimal candidates for the CardiAMP therapy. 

  The CardiALLO MSC platform is also approved for clinical investigation for the pulmonary indication of acute respiratory distress.